



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
MAY 15 2003
TECH CENTER 1600/2300

Applicant: H. Lowenheim Attorney Docket No.: SOPH116953
Application No.: 09/622,719 Group Art Unit: 1635
Filed: October 18, 2000 Examiner: K.A. Lacourciere
Title: METHOD FOR THE TREATMENT OF DISEASES OR DISORDERS OF
THE INNER EAR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Seattle, Washington 98101

May 7, 2003

TO THE COMMISSIONER FOR PATENTS:

Applicant is aware of the information listed in the attached form that may be material to the prosecution of the above-identified patent application.

1. X Copies of the listed patent, publications, and other information are enclosed for the Examiner's use. Documents O1-O5 were submitted on November 17, 2000, but were not considered by the Examiner.
2. X A concise explanation of the relevance of document Cite No. F1 (which is not in the English language), as presently understood by the individual designated under 37 C.F.R. § 1.56(c) most knowledgeable about its content, is provided in an English abstract appended to said document. Additionally, issued U.S. Patent No. 6,066,652 is the U.S. counterpart to this published, German language, international patent application. The English abstract of document F1 was also submitted on November 17, 2000.
3. X Pursuant to 37 C.F.R. § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in 37 C.F.R. § 1.97(b) but before the mailing date of a final action under 37 C.F.R. § 1.113, a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, and is accompanied by the submission fee set forth in 37 C.F.R. § 1.17(p). Check No. 147837 in the amount of \$180.00 is enclosed.

05/14/2003 DTESSEM1 00000107 09622719

01 FC:1806


180.00 DP

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{LLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

4. X The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.18 which may be required during the entire pendency of the application, or credit any overpayment, to Deposit Account No. 03-1740. This authorization also hereby includes a request for any extensions of time of the appropriate length required upon the filing of any reply during the entire prosecution of this application. A copy of this document is enclosed.

Respectfully submitted,

CHRISTENSEN O'CONNOR
JOHNSON KINDNESS^{PLC}



Barry F. McGurl
Registration No. 43,340
Direct Dial No. 206.695.1775

I hereby certify that this correspondence is being deposited with the U.S. Postal Service in a sealed envelope as first class mail with postage thereon fully prepaid and addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the below date.

Date:

5/7/03



BFM:jlj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{PLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100



FIRST SUPPLEMENTAL INFORMATION CITED BY APPLICANT THAT MAY BE
MATERIAL TO THE PROSECUTION OF THE SUBJECT APPLICATION

Applicant: H. Lowenheim Attorney Docket No. SOPH116953
Application No.: 09/622,719 Group Art Unit: 1635
Filed: October 18, 2000 Examiner: K. A. Lacourciere
Title: METHOD FOR THE TREATMENT OF DISEASES OR DISORDERS OF
THE INNER EAR

RECEIVED

MAY 15 2003

TECH CENTER 1600/2300

U.S. PATENT DOCUMENTS

*Examiner Cite	Kind	Date	
Initials No.	Document No.	Code	(mm/dd/yyyy) Name
_____ U1	6,066,652		05/23/2000 Zenner et al.

FOREIGN PATENT DOCUMENTS

*Examiner Cite	Kind	Publication Date	Country	English Abstract Provided	Translation Provided
Initial No.	Document No.	Code	(mm/dd/yyyy)		
_____ F1	WO 97/04762	A1	02/13/1997	WIPO	X

OTHER INFORMATION

(Including Author, Title, Date, Pertinent Pages, Etc.)

*Examiner Cite	
Initial No.	
_____ O1	Birnbaum, J.E., et al., "Effects of Reserpine, Epidermal Growth Factor, and Cyclic Nucleotide Modulators on Epidermal Mitosis," <i>Journal of Investigative Dermatology</i> 66(05):313-318, 1976 (ACS Abstract No. 85:13565).
_____ O2	Dal Bo, A. and A. Pitotti, "The Effects of β -Lactoglobulin Genetic Variants A and B on the Functional Properties of Whey Under Different Conditions," <i>Food Hydrocolloids</i> 11(1):41-48, 1997 (BIOSIS Abstract No. 1997:408589).
_____ O3	Huang, M.-T., et al., "Inhibitory Effects of Curcumin on Tumorigenesis in Mice," <i>Journal of Cellular Biochemistry Supplement</i> 27:26-34, 1997 (ACS Abstract No. 129:62545).

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESS^{LLC}
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100

- _____ O4 Shankland, S.J., et al., "Mesangial Cell Proliferation Mediated by PDGF and bFGF Is Determined by Levels of the Cyclin Kinase Inhibition p27(Kip1)," *Kidney Int. 51(4):1088-1099, 1997* (EMBASE Abstract No. 97130705).
- _____ O5 Simson, R., et al., "Evaluating the In Vivo Elastic Properties of Different Strands of Dictyostelium Discoideum Using Small Shear Forces," Technische Universität, München, Germany Abstract (BIOSIS Abstract No. 1997:441346).

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

BFM:jlj

LAW OFFICES OF
CHRISTENSEN O'CONNOR JOHNSON KINDNESSTM
1420 Fifth Avenue
Suite 2800
Seattle, Washington 98101
206.682.8100